What happened
Santen Pharmaceutical's R&D division reached a 93% weekly usage rate for generative AI, applying it to study plans, reports, searchable meeting minutes, and a truckload of documents.
Why it matters
Generative AI appears to be moving from trial to daily routine in pharma R&D work such as document creation and information gathering, which may reduce manual document handling.
WHO IT HITSPharma R&D and regulatory documentation teams that handle large volumes of study plans, reports and meeting records may see similar pressure to adopt generative AI for drafting and retrieval.
Summaries like this, in your inbox every morning.
Generative AI is becoming embedded in Santen Pharmaceutical's day-to-day operations rather than remaining a pilot experiment. The R&D division's weekly usage rate of 93% suggests the tool has moved into routine use across the team.
The company applies the technology to writing study plans and reports, and it has made meeting minutes searchable so that information gathering is more efficient. Alongside these uses, Santen has digitized a volume of documents described as a truckload, pointing to a broader push to convert paper records into usable data.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Amazon launched two Bee "personal AI" devices on Thursday: the $74.99 Bee Frontier wristband and the $99.99 Be…
Chip stocks pared losses after a debt-driven AI sell-off
Apple released MLX today, which runs the 816B-parameter Muse Spark Open on four Mac Studios at over 36 tokens…
Meta and Apple revealed Thursday that developers can run Meta's new open-weight Muse Spark Open model locally…
Bloom Energy stock fell 4% to $229.83, still up 165% year to date, while Caterpillar slipped 3% to $727.55 and…
The S&P 500 closed up 0.33% at 7,744.06 points, as Eli Lilly gained over 3%, UnitedHealth added 2.8% and Walma…
